4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Codes in Amended SEC Filing

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct transaction codes related to recent stock purchases.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amended Form 4 with the SEC on July 31, 2024.
• The amendment corrects an administrative error in the original filing from April 19, 2024, which incorrectly used transaction code 'A' instead of 'P'.
• The corrected form reflects purchases of Brainstorm Cell Therapeutics common stock on April 17 and April 18, 2024.
• On April 17, 2024, Lebovits purchased 130,000 shares at a weighted average price of $0.5457, with prices ranging from $0.5392 to $0.555.
• On April 18, 2024, Lebovits purchased 115,072 shares at a weighted average price of $0.5255, with prices ranging from $0.4936 to $0.59.
• Following these transactions, Lebovits directly owns 843,565 shares and may be deemed the beneficial owner of 2,000,847 indirectly owned shares.
• These indirectly owned shares include 1,933,794 shares held by ACCBT Corp. and 67,053 shares held by ACC International Holdings Ltd.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider trading activity and provides transparency to investors regarding the transactions of company executives.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

SEC Form 4, amendment, stock purchase, Chaim Lebovits, Brainstorm Cell Therapeutics, BCLI, beneficial ownership